Hey Spyon, I hear your concerns but I think it is difficult to...

Hey Spyon, I hear your concerns but I think it is difficult to comment accurately without seeing the half yearly report in Jan to understand exactly how much cash they have on hand and expected revenue for the next 6 months.

There will be significant costs involved with getting approval for an OTC S3 product with the biggest hurdle identifying and proving the product is medically beneficial in some way.

Whilst this may seem worrying for some I am going to expect them to need to raise money again this year and keep some cash on hand ready to partake in the SPP.

If they can actually achieve what I mentioned before over the next 24 months I am very bullish on the potential returns and will remain that way.

Happy to hear the thoughts of others as always, I for one continue to be glad they are minimising debt and continue to raise money in other ways.